Market Scenario
Costochondritis is an inflammatory condition of the cartilage which connects a rib to the sternum. It is sometimes called chest wall pain, costosternal chondrodynia, or costosternal syndrome. The pain caused by costochondritis might be similar to that of a heart attack. Costochondritis is a common cause of chest pain in adolescents and children. It is estimated that the global costochondritis treatment market is expected to register an increasing CAGR during the forecast period from 2018 to 2023.
The factors causing costochondritis can be injury in chest, physical strain, osteoarthritis, arthritis, ankylosing spondylitis, and tumors (cancerous or noncancerous). Also, costochondritis may be caused by bacterial, viral, and fungal infections. According to the Centers for Disease Control and Prevention, August 2018, it has been estimated that 22.7% of the US adults had some form of rheumatoid arthritis from 2013 to 2015. The growing percentage of arthritis patients would support the costochondritis market positively.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6500
However, factors such as the high cost of surgical procedures, expensive treatments, and side effects related to treatments are expected to restrict the market growth during the forecast period.
Segmentation
The global costochondritis market is segmented on the basis of diagnosis, treatment, and end-user. The costochondritis market, by diagnosis, is categorized into various tests. The test is sub-segmented into echocardiogram, electrocardiogram, stress tests, cardiac catheterization, chest X-ray, cardiac MRI, and CT scan. On the basis of treatment, the market is segmented into medications, therapy, and surgery.
The medications treatment is further sub-segmented into nonsteroidal anti-inflammatory drugs, narcotics, antidepressants, and anti-seizure drugs. Therapy is sub-segmented into stretching exercises and nerve stimulation. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.
On the basis of region, the global costochondritis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the UAE, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key players
Some of the key players in the global costochondritis market are KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc., Recro Pharma Inc., LUPIN, Bausch Health Companies Inc., Avenue Therapeutics, and others.
Regional Market Summary
It is estimated that North America dominated the global costochondritis market owing to the increased cardiac diseases, increasing prevalence of syphilis, innovations in clinical practice, heart research, and access to heart treatments in this region. According to the Centers for Disease Control and Prevention (CDC), September 2017, the total syphilis cases reported to CDC increased by 17.8% during 2015 to 2016. The increase in the cases of syphilis supports the market growth in this region.
Europe stood the second largest in the costochondritis market owing to increasing hypertension and heart attack cases. According to the Public Health England in January 2017,
high blood pressure is the third highest risk factor for disease in the UK. It affected one in four adults and around 12.5 million people in 2015 in England. This number is expected to increase during the forecast period. Such a high incidence of high blood pressure supports the growth of costochondritis in this region.
Asia-Pacific was estimated to be the fastest growing region for the global costochondritis market in 2017. The market is expected to witness growth owing to the rising prevalence of heart problems, car accidents, and changing lifestyle.
The Middle East and Africa holds the least share in the global costochondritis market due to the presence of low health expenditure, low awareness of innovative technology, and economically diverse countries. However, the market is expected to witness growth due to increasing cardiac care programs and an increase in investments in research and development in the Middle East.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/costochondritis-market-6500
No comments:
Post a Comment